Information Hub
Access guidance, webcasts and publications with commentaries using the ABS Information Hub. Search by classification or using keywords.
To view the webcasts from previous ABS Conferences, events and webinars you must be an ABS member and be logged in using your membership username and password.
-
menu_book
Using the database of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), this study investigates rates of distant breast-cancer recurrence in oestrogen receptor-positive and oestrogen re...
Early Breast Cancer Trialists' Collaborative Group | The Lancet
28.11.2024 | Added: 28.11.2024
Classifications: Screening & Diagnosis
menu_bookPublication menu_book -
menu_book
MonarchE is an open-label, randomised, phase 3 trial which recruited high risk hormone receptor positive, HER2 receptor negative, node-positive breast cancer patients (n=5637). Patients were randomise...
Prof Stephen R D Johnston, MD et al | The Lancet Oncology
06.12.2022 | Added: 06.12.2022
Classifications: Adjuvant & Neoadjuvant Treatment
Keywords: Adjuvant treatment Endocrine therapy Trials
menu_bookPublication menu_book -
menu_book
Thiruchelvam et al have recently reported on their study, PRADA, to explore the feasibility of preoperative radiotherapy followed by skin-sparing mastectomy and deep inferior epigastric perforator (DI...
Paul T R Thiruchelvam et al | The Lancet Oncology
07.04.2022 | Added: 07.04.2022
Classifications: Breast & Oncoplastic Surgery
Keywords: Flaps Radiotherapy Breast Reconstruction
menu_bookPublication menu_book -
menu_book
This pooled analysis of 2310 patients from four neoadjuvant clinical trials examined survival and treatment response in patients with HER2-low-positive (immunohistochemistry 1+ or 2+/in-situ hybridisa...
Prof Carsten Denkert et al | The Lancet Oncology
09.07.2021 | Added: 09.07.2021
Classifications: Breast Cancer Treatment
Keywords: HER2 Positive
menu_bookPublication menu_book -
menu_book
This study aimed to examine the planned long-term recurrence and survival outcomes from the ELIOT trial. Eligible women, aged 48-75 years with a clinical diagnosis of a unicentric breast carcinoma wit...
Prof Roberto Orecchia et al | The Lancet Oncology
01.05.2021 | Added: 01.05.2021
Classifications: Adjuvant & Neoadjuvant Treatment
Keywords: Trials Intraoperative Radiotherapy
menu_bookPublication menu_book -
menu_book
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Young patients with breast cancer and BRCA mutation have similar survival to sporadic breast cancer patients (POSH trial)
Ellen R Copson et al | The Lancet Oncology
19.02.2018 | Added: 19.02.2018
Classifications: Breast Cancer Risk
Keywords: BRCA Management of the younger patient
menu_bookPublication menu_book
